Company news
Alphamab Oncology news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC
March 17, 2025
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
February 27, 2025
Voluntary announcement - abstracts and e-posters of research updates on KN046 and KN026 for presentation at 2021 asco annual meeting
May 6, 2021
Alphamab Oncology: (1) Proposed granting of general mandates to repurchase shares and to issue new shares; (2) proposed re-election of the retiring directors; (3) proposed re-appointment of auditors; and (4) notice of annual general meeting
April 27, 2021
Voluntary announcement - preliminary safety tolerability and efficacy results of KN046 in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer released for e-poster presentation at 2021 aacr annual meeting
April 12, 2021
Voluntary announcement - appointment of chief medical officer and chief financial officer
March 30, 2021
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights
March 23, 2021
Alphamab Oncology: Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
March 9, 2021
Voluntary announcement - ind approval received for a phase ii clinical trial of KN046 in the U.S.
March 8, 2021
Alphamab Oncology: Received U.S. FDA IND Approval to Initiate A Phase II Clinical Trial of KN046 For NSCLC in the United States
April 16, 2020
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib)
March 27, 2020